olive
Approved
Oct 3, 2013
The olive, is a species of subtropical evergreen tree in the family Oleaceae. Originating in Asia Minor, it is abundant throughout the Mediterranean Basin, with wild subspecies in Africa and western Asia; modern cultivars are traced primarily to the Near East, Aegean Sea, and Strait of Gibraltar. The olive is the type species for its genus, Olea, and lends its name to the Oleaceae plant family, which includes lilac, jasmine, forsythia, and ash. The olive fruit is classed botanically as a drupe, similar in structure and function to the cherry or peach. The term oil—now used to describe any viscous water-insoluble liquid—was once synonymous with olive oil, the liquid fat derived from olives. — Wikipedia
Clinical trial activity
194 trials · 247 clinical orgs · 2 marketing orgs
Earliest trial started Nov 1, 1989 (NCT01353807)
Timeline
1800s
- Jan 1, 1800
Evidence of US Marketing
1990s
- Jan 1, 1999
Earliest Phase 3 Sponsor(trial)
Indications
Approved for
Studied for
- Anemia · Phase 4
- Anemia, Sickle Cell · Phase 2
- Asthma · Phase 3
- Biological Availability · Phase 1/Phase 2
- Blood Glucose · Phase 1
- Bone Diseases, Metabolic · Phase 4
- Brain · Phase 4
- Brain Diseases · Phase 2
- Cardiovascular Diseases · Phase 3
- Central Nervous System Diseases · Phase 2
- Child Development · Phase 3
- Chronic Periodontitis · Phase 4
- Cognition · Phase 4
- Cognition Disorders · Phase 3
- Cognitive Dysfunction · Phase 2
- Colonoscopy · Phase 4
- COVID-19 · Phase 2
- Croup · Phase 3
- Dementia · Phase 2
- Depression · Phase 3
- Dermatitis · Phase 1/Phase 2
- Diabetes Mellitus · Phase 3
- Diabetes Mellitus, Type 2 · Phase 2
- Dietary Supplements · Phase 1
- Disseminated Intravascular Coagulation · Phase 2
- Dry Eye Syndromes · Phase 4
- Dysbiosis · Phase 2/Phase 3
- Dyslipidemias · Phase 4
- Eczema · Phase 3
- Enteral Nutrition · Phase 1/Phase 2
- Enterococcus faecalis · Phase 2/Phase 3
- Fatty Acids · Phase 4
- Fatty Acids, Omega-3 · Phase 4
- Fractures, Bone · Phase 3
- Functional Food · Phase 1/Phase 2
- Gingivitis · Phase 2
- Healthy Volunteers · Phase 1/Phase 2
- Hemodialysis, Home · Phase 4
- Hypercholesterolemia · Phase 4
- Hyperglycemia · Phase 4
- Hypersensitivity · Phase 3
- Hypertension · Phase 4
- Hypertriglyceridemia · Phase 3
- Infant, Premature · Phase 2/Phase 3
- Inflammation · Phase 2
- Intestinal Neoplasms · Phase 3
- Keratoconjunctivitis Sicca · Phase 2/Phase 3
- Kidney Failure, Chronic · Phase 4
- Leukemia · Phase 1
- Low Back Pain · Phase 2
- Lupus Erythematosus, Systemic · Phase 2
- Menopause · Phase 4
- Mental Disorders · Phase 3
- Metabolic Syndrome · Phase 4
- Neonatal Sepsis · Phase 2/Phase 3
- Nervous System Diseases · Phase 2
- Neurocognitive Disorders · Phase 2
- Neurosciences · Phase 4
- Nutritional Physiological Phenomena · Phase 1/Phase 2
- Obesity · Phase 4
- Obstetric Labor, Premature · Phase 2
- Osteoarthritis · Phase 2
- Osteoarthritis, Knee · Phase 2
- Osteoporosis · Phase 2
- Oxidative Stress · Phase 1
- Pain · Phase 2
- Papillomavirus Infections · Phase 2
- Parenteral Nutrition · Phase 4
- Pathologic Processes · Phase 2
- Pemphigoid, Bullous · Phase 3
- Pemphigus · Phase 3
- Periodontal Diseases · Phase 2
- Periodontitis · Phase 1/Phase 2
- Physiology · Phase 1
- Polycystic Ovary Syndrome · Phase 4
- Pregnancy · Phase 3
- Pressure Ulcer · Phase 4
- Psoriasis · Phase 2/Phase 3
- Radiodermatitis · Phase 4
- Respiratory Sounds · Phase 3
- Respiratory Tract Infections · Phase 3
- Schizophrenia · Phase 4
- Sepsis · Phase 2/Phase 3
- Signs and Symptoms · Phase 2
- Sjogren's Syndrome · Phase 4
- Stomatitis · Phase 1
- Tobacco Use Disorder · Phase 2
- Tooth Movement Techniques · Phase 1
- Vitamin D Deficiency · Phase 4
Mechanism of action
- Unspecified targetSupplementation
supplementation
Combination products
clinolipi
with soybean oil
smoflipi
Approval history
- approvedPriority reviewOct 3, 2013
- approvedPriority reviewJan 1, 1800
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaOlive ↗
- NCATS6UYK2W1W1E ↗
- WikipediaOlive leaf ↗
- ChEMBLCHEMBL2107910 ↗
- NCATS2M6QWV94OC ↗
- NCATS6HD2W46UEG ↗
- WikipediaOlive oil ↗
Also known as
- olive extract
- olive leaf extract
- olive oil
- olive oil
- olive oil
- olive oil
- olive polyphenol
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06880939 | N/A | Jul 15, 2025 | Qingdao University, Shandong Provincial Hospital, Shandong University |
| NCT07008586 | N/A | Jul 1, 2025 | Anglia Ruskin University, Antonio e Bandino Lo Franco Soc. Agr. Sempl. |
| NCT06990282 | Phase 2 | Jul 1, 2025 | Fayoum University |
| NCT07210099 | N/A | May 30, 2025 | Anglia Ruskin University |
| NCT07127705 | N/A | May 21, 2025 | Natural Immune Systems Inc |
| NCT06971445 | N/A | May 14, 2025 | Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes |
| NCT06880926 | Phase 2 | Apr 1, 2025 | Shandong University |
| NCT07197073 | N/A | Feb 25, 2025 | Alexandria University |
| NCT06737484 | N/A | Feb 3, 2025 | Inonu University, Kahramanmaras Sutcu Imam University |
| NCT06723886 | N/A | Jan 15, 2025 | Government of Spain, Universidad Complutense de Madrid |
| NCT06570889 | Phase 3 | Nov 30, 2024 | University of Copenhagen |
| NCT06983145 | N/A | Nov 20, 2024 | University of the Aegean |
| NCT06567951 | N/A | Sep 10, 2024 | Universidad de los Andes, Universidad San Sebastián |
| NCT07144488 | N/A | Sep 1, 2024 | Apostolos Loukas Medical Centre Cyprus, University of Athens, University of Crete, Yale University |
| NCT06285682 | N/A | Feb 3, 2024 | Anglia Ruskin University |
| NCT06621966 | N/A | Jan 10, 2024 | RAK Medical and Health Sciences University |
| NCT06972134 | N/A | Dec 15, 2023 | Duhok University |
| NCT06070311 | N/A | Oct 31, 2023 | Assiut University |
| NCT06072625 | N/A | Oct 1, 2023 | Uludag University |
| NCT06006663 | Phase 2/Phase 3 (Phase 3) | Aug 26, 2023 | Tanta University |
Organizations
Research & Development (247)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of Spain | Government | 10 | 3 | 2 | 2009 |
| BASF | For profit | 4 | 0 | 2 | 2015 |
| Northumbria University | Academic/Hospital | 4 | 4 | 1 | 2016 |
| University of Copenhagen | Academic/Hospital | 4 | 3 | 2 | 1990 |
| University of Granada | Academic/Hospital | 4 | 3 | 2 | 2020 |
| University of Reading | Academic/Hospital | 4 | 4 | 1 | 2011 |
| Ain Shams University | Academic/Hospital | 3 | 2 | 3 | 2022 |
| Anglia Ruskin University | Academic/Hospital | 3 | 3 | 1 | 2024 |
| Auburn University | Academic/Hospital | 3 | 3 | 1 | 2017 |
| Centre for Fetal Programming, Denmark | Academic/Hospital | 3 | 2 | 1 | 1989 |
| Nestle | For profit | 3 | 2 | 1 | 2020 |
| The University of Texas, Dallas | Academic/Hospital | 3 | 3 | 2 | 2010 |
| Universidad Complutense de Madrid | Academic/Hospital | 3 | 3 | 1 | 2018 |
| University of Athens | Academic/Hospital | 3 | 0 | 1 | 2018 |
| University of Sao Paulo | Academic/Hospital | 3 | 2 | 3 | 2010 |
| Yale University | Academic/Hospital | 3 | 2 | 1 | 2019 |
| Zhejiang University | Academic/Hospital | 3 | 3 | 1 | 2020 |
| Andalusian Health Service | Academic/Hospital | 2 | 0 | 2 | 2021 |
| Antonio e Bandino Lo Franco Soc. Agr. Sempl. | Academic/Hospital | 2 | 0 | 1 | 2021 |
| Ardabil University of Medical Sciences | Academic/Hospital | 2 | 2 | 1 | 2008 |